Lanifibranor – 50 mg

Brand:
Cayman
CAS:
927961-18-0
Storage:
-20
UN-No:
Non-Hazardous - /

Lanifibranor is an agonist of peroxisome proliferator-activated receptors (PPARs) with EC50 values of 1,537, 866, and 206 nM for human recombinant PPARα, PPARβ, and PPARγ, respectively, for transactivation activity.{42553} It increases β-oxidation in Huh-7 and C2C12 cells when used at concentrations of 1 and 3 µM, respectively, and increases the expression of the PPARγ target genes adipocyte protein 2 (aP2) and adiponectin in adipocytes. Lanifibranor reduces plasma glucose and triglyceride levels in a db/db mouse model of type 2 diabetes when administered at doses of 10 and 30 mg/kg for five days. It also increases plasma adiponectin levels and decreases collagen deposition in a carbon tetrachloride-induced mouse model of non-alcoholic steatohepatitis (NASH).  

 

Available on backorder

SKU: 25572 - 50 mg Category:

Description

A PPAR agonist (EC50s = 1,537, 866, and 206 nM for human recombinant PPARα, PPARβ, and PPARγ, respectively); increases β-oxidation in Huh-7 and C2C12 cells at 1 and 3 µM, respectively; reduces plasma glucose and triglyceride levels in a db/db mouse model of type 2 diabetes at 10 and 30 mg/kg for five days; increases plasma adiponectin levels and decreases collagen deposition in a carbon tetrachloride-induced mouse model of NASH


Formal name: 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid

Synonyms:  IVA337

Molecular weight: 434.9

CAS: 927961-18-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors|PPARs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH